OBJECTIVE: The authors' goal was to investigate phosphatidylinositol and glutamatergic metabolism in the anterior cingulate cortex of children and adolescents with attention deficit hyperactivity disorder (ADHD) alone, children with ADHD plus bipolar disorder, and children with no axis I diagnosis. METHOD: Proton spectra were acquired from a 4.8-ml voxel placed in the anterior cingulate cortex of 30 subjects who were 6 to 13 years old. Fifteen subjects had ADHD and no comorbid disorder, eight had ADHD plus bipolar disorder, and seven were healthy comparison subjects. RESULTS: Children with ADHD had a significantly higher ratio of glutamate plus glutamine to myo-inositol-containing compounds than children with ADHD plus bipolar disorder and healthy children. CONCLUSIONS: myo-Inositol-containing compounds may provide information on the action of antimanic treatments such as lithium, valproate, and carbamazepine. Glutamate and glutamine are measures of glutamatergic neurotransmission and thus may also reflect changes in serotonin and dopamine pathways.
OBJECTIVE: The authors' goal was to investigate phosphatidylinositol and glutamatergic metabolism in the anterior cingulate cortex of children and adolescents with attention deficit hyperactivity disorder (ADHD) alone, children with ADHD plus bipolar disorder, and children with no axis I diagnosis. METHOD: Proton spectra were acquired from a 4.8-ml voxel placed in the anterior cingulate cortex of 30 subjects who were 6 to 13 years old. Fifteen subjects had ADHD and no comorbid disorder, eight had ADHD plus bipolar disorder, and seven were healthy comparison subjects. RESULTS:Children with ADHD had a significantly higher ratio of glutamate plus glutamine to myo-inositol-containing compounds than children with ADHD plus bipolar disorder and healthy children. CONCLUSIONS:myo-Inositol-containing compounds may provide information on the action of antimanic treatments such as lithium, valproate, and carbamazepine. Glutamate and glutamine are measures of glutamatergic neurotransmission and thus may also reflect changes in serotonin and dopamine pathways.
Authors: C M Moore; J L Breeze; S A Gruber; S M Babb; B B Frederick; R A Villafuerte; A L Stoll; J Hennen; D A Yurgelun-Todd; B M Cohen; P F Renshaw Journal: Bipolar Disord Date: 2000-09 Impact factor: 6.744
Authors: Pablo Davanzo; Kenneth Yue; M Albert Thomas; Thomas Belin; Jim Mintz; T N Venkatraman; Eliana Santoro; Sarah Barnett; James McCracken Journal: Am J Psychiatry Date: 2003-08 Impact factor: 18.112
Authors: Erin M Miller; Francois Pomerleau; Peter Huettl; Greg A Gerhardt; Paul E A Glaser Journal: Psychopharmacology (Berl) Date: 2014-02-28 Impact factor: 4.530
Authors: Ana A Liso Navarro; Elif M Sikoglu; Cailin R Heinze; Ryan C Rogan; Vivienne A Russell; Jean A King; Constance M Moore Journal: Behav Brain Res Date: 2014-05-19 Impact factor: 3.332
Authors: Daniel P Dickstein; Elizabeth C Finger; Martha Skup; Daniel S Pine; James R Blair; Ellen Leibenluft Journal: Bipolar Disord Date: 2010-11 Impact factor: 6.744
Authors: Joseph Biederman; Stephen V Faraone; Carter Petty; Marykate Martelon; K Yvonne Woodworth; Janet Wozniak Journal: J Psychiatr Res Date: 2012-09-11 Impact factor: 4.791
Authors: Daniel P Dickstein; Kenneth E Towbin; Jan Willem Van Der Veen; Brendan A Rich; Melissa A Brotman; Lisa Knopf; Laura Onelio; Daniel S Pine; Ellen Leibenluft Journal: J Child Adolesc Psychopharmacol Date: 2009-02 Impact factor: 2.576
Authors: Daniel P Dickstein; Brendan A Rich; Roxann Roberson-Nay; Lisa Berghorst; Deborah Vinton; Daniel S Pine; Ellen Leibenluft Journal: Bipolar Disord Date: 2007-11 Impact factor: 6.744
Authors: Robert D Oades; Maria R Dauvermann; Benno G Schimmelmann; Markus J Schwarz; Aye-Mu Myint Journal: Behav Brain Funct Date: 2010-05-28 Impact factor: 3.759